Recipharm puts up $45M to enhance track-and-trace capabilities

With new rules looming in Europe, contract drugmaker Recipharm intends to invest $45 million (€40 million) over the next three years to improve its drug traceability capabilities for clients. It will invest across its manufacturing network to add new coding and serialization technologies that will enable products to be tagged and traced with identifiable markers that can help thwart counterfeiting. The move comes on the heels of the EU Falsified Medicines Directive, which will require new measures in drug manufacturing starting in 2019. More from FierceCRO

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.